The researchers, including those from the New York University in the US, found that remdesivir was most beneficial for hospitalised patients with severe disease requiring supplemental oxygen New York: Remdesivir, the antiviral under clinical trials for treatment against novel coronavirus infection, is superior to the standard of care given to COVID-19 patients, according to a new study.
The analysis, published in the New England Journal of Medicine, is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in the US.
In the randomised, controlled trial, clinicians enrolled adults hospitalised with COVID-19 who showed infection in the lower respiratory